Effect of nonnicotine pharmacotherapy on smoking behavior

Michael Kotlyar, Michael Golding, Dorothy K. Hatsukami, Brenda D. Jamerson

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


Smoking-related disease is the single biggest preventable cause of morbidity and mortality in the United States, yet approximately 25% of Americans continue to smoke. Various dosage forms of nicotine replacement therapy increase smoking quit rates relative to placebo, but they generally do not result in 1-year quit rates of over 20%. To increase these rates, a number of nonnicotine agents have been investigated. Drugs that modulate noradrenergic neurotransmission (bupropion, nortriptyline, moclobemide) are more effective than those affecting serotonin (selective serotonin reuptake inhibitors, buspirone, ondansetron) or other neurotransmitters.

Original languageEnglish (US)
Pages (from-to)1530-1548
Number of pages19
Issue number12
StatePublished - 2001


Dive into the research topics of 'Effect of nonnicotine pharmacotherapy on smoking behavior'. Together they form a unique fingerprint.

Cite this